Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Overview of attention for article published in Arthritis Research & Therapy, August 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

So far, Altmetric has seen 9 X posts from 6 X users, with an upper bound of 11,729 followers.

And don't miss our papers on Abatacept (http://t.co/B0row49KtO) and Nilotinib (http://t.co/erWw1VzK0x) therapies in scleroderma.

RT @ArthritisRes: Pilot clinical trial: Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis http://t.co/6mA1cvec5e #r…

RT @ArthritisRes: Pilot clinical trial: Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis http://t.co/6mA1cvec5e #r…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.